VereCoV

VereCov2

VereCoV

Detects and Identifies: 2019 Novel Coronavirus (2019-nCov) i.e. Wuhan Coronavirus Severe Acute Respiratory Syndrome-related Coronavirus (SARS-CoV)Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Rapid Detection and Identification of 2019-nCoV, MERS-CoV and SARS-CoV

Coronaviruses (CoV) are a family of viruses resulting in illnesses ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome (SARS-CoV) and the most recent, 2019 novel Coronavirus (2019-nCoV). Chinese authorities first identified 2019-nCov and discovered it to be approximately 70% similar to SARS-CoV in genomic sequence.

Severe cases of infection may cause pneumonia, severe acute respiratory syndrome, kidney failure and even death. The World Health Organization (WHO) estimated the overall fatality rate for SARS at 14% to 15%, and MERS-CoV at 35%.

Given high transmission rates of SARS-CoV and MERS- CoV, it is possible that the 2019-nCoV could also cause high incidences of transmission. This could easily escalate to a global outbreak, and as such, the need for an accurate and reliable test for surveillance and detection is essential.

To meet this need, Veredus offers a new solution: VereCoV™, a portable Lab-on-Chip application. Together with the VerePLEX™ Lab-on-Chip Platform, it is capable of detecting, differentiating and identifying MERS-CoV, SARS-CoV and the 2019-nCoV in a single test.

Specifications

Detects 2019-nCoV, MERS-CoV and SARS-CoV

Multiple Probes (with duplicates) for:

• 2019-nCoV specific targets

• MERS-CoV specific targets

• SARS-CoV specific targets

Process Controls on each chip:

• PCR: Positive Control

• Hybridization: Orientation Probes, Positive Control Probes, Negative Control

Sample Types*: respiratory swabs (nasopharyngeal, nasal, throat, or throat aspirates)

Every chip is bar-coded and measures 2.54 cm x 7.62 cm

Advantages

Speed• RNA samples to results in less than 2.5 hours

Comprehensive• Detection of specific targets for 2019-nCoV,

MERS-CoV and SARS-CoV surveillance and enables prompt action by healthcare authorities to control outbreaks

Easy to use

• Detects 2019-nCoV, MERS-CoV and SARS- CoV without cross-reactivity with other coronaviruses such as OC43, 229E, KHU1, NL63

Mobile• The VerePLEX™ Biosystem is designed to be portable for usage at areas such as checkpoints and borders.

Easy to use

• The simple workflow allows for minimally trained or non-scientific personnel to run tests

Updates Available

• Probes can be updated quickly to include new mutations of the evolving Coronaviruses and ensure the right coverage of detection

 

VereCoV

Leave a Reply

Your email address will not be published. Required fields are marked *